Notably, a much higher dynamism has been reported for HER2-low and HER2-negative BCs with a relevant portion of HER2-low tumors turning HER2-zero, and vice versa, either on residual disease after neoadjuvant therapy [11], or following tumor relapse [[12], [13], [14]]. The gene discussed is ERBB2; the disease is neoplasm.